(NASDAQ: TPST) Tempest Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 66.55%.
Tempest Therapeutics's earnings in 2026 is -$40,472,000.On average, 3 Wall Street analysts forecast TPST's earnings for 2026 to be -$46,452,148, with the lowest TPST earnings forecast at -$44,630,495, and the highest TPST earnings forecast at -$47,818,387. On average, 3 Wall Street analysts forecast TPST's earnings for 2027 to be -$14,669,099, with the lowest TPST earnings forecast at -$14,093,841, and the highest TPST earnings forecast at -$15,100,543.
In 2028, TPST is forecast to generate -$14,506,109 in earnings, with the lowest earnings forecast at -$13,937,242 and the highest earnings forecast at -$14,932,760.